Otros idiomas Travere Therapeutics, Inc.

Acciones

TVTX

US89422G1076

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 13/02/2026			Variación 5 días	Varia. 1 de enero.
27,82 ^USD	-9,08 %		-6,36 %	-27,19 %

28/01	Un directivo de Travere Therapeutics vendió acciones por un valor de 1.805.134 dólares, según una reciente declaración ante la SEC	MT
23/01	TRAVERE THERAPEUTICS, INC. : El Wedbush continua con un recomendación de compra	ZM

Otros idiomas

12/02	Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
12/02	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
11/02	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/02	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
28/01	Travere Therapeutics Insider Sold Shares Worth $1,805,134, According to a Recent SEC Filing
17/01	Travere Therapeutics : Corporate Overview – January 2026
17/01	Travere Therapeutics : Investor Fact Sheet
16/01	Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses
16/01	TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
14/01	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI in FSGS
14/01	Dimerix's Drug Candidate Approval by FDA Unrelated to US Peer's New Drug Application Approval Date
14/01	TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
13/01	Sector Update: Health Care Stocks Softer Late Afternoon
13/01	Sector Update: Health Care
13/01	Travere Therapeutics, Inc. Announces FDA Extends Review of sNDA for Filspari®? in Focused Segmental Glomerulosclerosis
13/01	Top Midday Decliners
13/01	Travere Therapeutics Says FDA Extends Review of Filspari to April; Shares Fall
13/01	Travere Therapeutics Shares Fall After FDA Extends Filspari Review
13/01	Travere shares fall as US FDA extends review of rare kidney disease drug
13/01	Travere Therapeutics says FDA extends review of sNDA for Filspari (sparsentan) in FSGS
13/01	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
13/01	Travere Therapeutics Shares Halted, Pending Material News Release
13/01	Top Premarket Decliners
13/01	Travere Therapeutics : Corporate Overview – January 2026
12/01	Travere Therapeutics provides corporate update and 2026 outlook

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Artículos de MarketScreener Estrategias MarketScreener Ideas de trading

Otros idiomas Travere Therapeutics, Inc.

Acciones

TVTX

US89422G1076

Biotecnología e investigación médica

Otros idiomas

Filtros